

# Indian Health Service All Tribal and Urban Indian Organization Leaders Call

---

JANUARY 6, 2022



# Opening Remarks



ELIZABETH FOWLER  
ACTING DEPUTY DIRECTOR  
INDIAN HEALTH SERVICE





# Tribal and Urban Indian Organization Leader Call January 6, 2021



---

LORETTA CHRISTENSEN, MD MBA MSJ FACS  
CHIEF MEDICAL OFFICER  
INDIAN HEALTH SERVICE



# Strategy 1 - Prevent

- Get vaccinated, including boosters!!!
- Continue to take all precautions!!!!
- The 3 W's:
  - Wear a mask
  - Wait 6 feet apart
  - Wash your hands



## Strategy 2 - Detect

---

- 3,644,317 tests have been performed, 9.2% positive
- IHS areas are in high transmission
  - The vast majority of these positive cases are the unvaccinated
- Current 7-day rolling positivity is 21.7%
- Home testing: QuickVue is available



# Omicron

---

- Replicates at a high rate in the upper airway which increases the transmissibility
  - Coughing, talking etc. will send the aerosol into the space
- Vaccination is the best protection
- Public health measures always are protective
  - Will need better masks or double masks in close spaces
- Omicron is now 95.4% of our cases
- The vaccinations are effective at preventing severe illness, hospitalization and death
- The booster doses are very important



# Strategy 3 - Treat

---

- Therapeutics: Monoclonal antibody therapy is available
  - Sotrovimab is effective against Omicron
- Critical Care Response Teams are still deploying
- The 2 oral antivirals are approved
  - Molnupiravir and Paxlovid
  - There is a limited supply at this time
  - Both are given in 5 day treatment



# Strategy 3 - Treat

---

- FDA issued an EUA for Evusheld (tixagevimab/cilgivimab)
- This is a long acting pre-exposure prevention of COVID-19
- Must still get vaccinated
- For immunocompromised patients or those on immunosuppressive therapy or severe adverse reaction to available COVID-19 vaccinations
- Protection for 6 months



# Strategy 4 - Recover

---

- Continue to address trauma, behavioral health, substance use disorder, grief and loss
- Monitoring and care of those who have had COVID-19 who may have Post-Covid or long Covid syndrome





# Vaccine Task Force Vaccine Update



RADM Francis Frazier

Director, Office of Public Health Support

Indian Health Service



# Recent Pfizer Changes

---

- **Booster Doses**

- Now **boosters are expanded to include individuals 12-15 years.**
  - Everyone 12 years and older should get a booster.
- The **booster interval was shortened from 6 months to 5 months** for the Pfizer vaccine.
  - Everyone should get a booster at least 5 months after receiving a Pfizer primary series.

- **Third Doses**

- Children **5 and older with weakened immune systems** should receive a **third dose** of Pfizer vaccine in their primary series, at least 28 days after the second dose.

- Data show that boosters help broaden and strengthen protection against Omicron and other variants. Expansion of the booster recommendations will provide optimized protection against COVID-19 and the Omicron variant.




# COVID-19 Vaccine Recommendations

---

- Everyone aged 5 years and older should receive a COVID-19 vaccine
  - The CDC preferentially recommends the Pfizer or Moderna vaccines over the Janssen/Johnson & Johnson vaccine.
  - If desired, the Janssen/Johnson & Johnson may still be used.
- If eligible for a booster, get one!
  - 12 years -17 years
    - At least 5 month after a Pfizer primary series.
  - 18 years and older
    - At least 2 months after a Janssen/Johnson & Johnson dose.
    - At least 5 months after a Pfizer primary series.
    - At least 6 months after a Moderna primary series.
  - Boosters significantly reduce the risk of severe COVID-19 infection
  - Any brand can be used as a booster – talk with your provider about which one is right for you



# Administration Data – CDC Tracker



GU AS RP FM MP MH VI

BoP DoD IHS VHA

Total Doses Administered per 100,000

○ No Data ○ 0 ○ 1 - 120,000 ○ 120,001 - 130,000 ○ 130,001 - 140,000 ○ 140,001 - 150,000 ○ 150,001 +

## National Data from CDC Tracker as of 1/4/2022

- Total delivered 614 million
- Total doses administered 512 million
- At least 1 dose administered 244 million (73.8%)
- Fully vaccinated 206 million (62.2%)
- Booster Dose 71 million (34.7% of fully vaccinated)

**Administration Rate 83%**

## IHS Data from CDC Tracker as of 1/4/2022

- Total distributed 2.54 million
- Total doses administered **2.03 million**
- At least 1 dose administered 1,029,852 (49.4% of 2.1 million total pop)
- Fully Vaccinated 820,830 (39.4% of 2.1 million total pop )
- Booster Dose 194,809 (23.7% of fully vaccinated of 2.1 million total pop)

**Administration Rate 80%**

### Notes:

- Data is pulled by CDC at 6am ET
- IHS data is sent at 1pm ET daily
- 2.1 million total population reflects AI/AN individuals, non-beneficiaries, health care personnel, and essential workers



# Fully Vaccinated and Up To Date Definitions

---

- The definition of fully vaccinated remains unchanged.
  - $\geq 2$  weeks after receipt of the second dose in a 2-dose series (Pfizer or Moderna) or  $\geq 2$  weeks after receipt of the Janssen/J&J vaccine.
- The CDC is emphasizing being "up to date" on boosters
  - Receiving the booster dose at the eligible time is considered being up to date
  - CDC encourages everyone to stay up to date on vaccinations – is reflected on the CDC website, "CDC recommends that people remain up to date with their vaccines, which includes [additional doses](#) for individuals who are immunocompromised or [booster doses](#) at regular time points"
  - Website: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>



# Looking Forward

---

- Adolescents
  - Moderna application for adolescents 12-17 years submitted to FDA, pending review
- Pediatrics
  - Moderna for ages 6-11 years: 2022, exact timeline unknown for submission of EUA application
  - Moderna for 6 months to 5 years: 2022, exact timeline unknown for submission of EUA application
  - Pfizer for 2 to 4 years: delayed until "first half of 2022"
    - Pfizer press release 12/17/21 indicated that the 2 to < 5 age group did not meet the pre-specified immune response
    - No safety concerns identified; favorable safety profile observed
    - A 3mcg, 2-dose series was studied
    - Pfizer decided to expand the trial and study a 3-dose series option





# All Tribal and Urban Indian Organization Leaders Call

---

- **Next Call:** Thursday, February 3, 2022 at 3:00 PM – 4:00 PM
- **IHS Event Calendar:** <https://www.ihs.gov/ihscalendar/>

